Looking forward, we expect to accomplish the following: file 2-3 new CTAs every year; target a new cell type with the TRiM™ platform every 18 months; and, have 10 TRiM™ enabled candidates in clinical studies by the end of 2020.” ir.arrowheadpharma.com/node/13976/pdf Expanding extrahepatic capabilities to now include delivery to the lung, tumor, and muscle tissue |